The Shotlee Journal
Browse Shotlee articles about Mounjaro.
Showing 9 / 801 Mounjaro articles
In 2024, the US pharmaceutical market crowned Keytruda (Merck & Co.) as the top-selling drug with $17.87 billion in revenue, according to Statista's 'Top pharmaceutical drugs' report. Oncology treatments like Keytruda lead, followed by diabetes heavyweights Ozempic and Mounjaro. This ranking underscores the shift toward biologics for cancer, diabetes, and autoimmune diseases.
In a pivotal head-to-head trial, Novo Nordisk's next-generation obesity drug CagriSema delivered 23% body weight reduction over 84 weeks, missing the mark against Eli Lilly's tirzepatide at 25.5%. This setback highlights the intense competition in the weight-loss market. Novo shares dropped 11%, while Lilly's rose 4%.
Katy Perry's noticeable weight loss transformation starting in 2023 has fans speculating about Ozempic use, even as she credits diet and hydration. Online chatter about 'Ozempic face' intensified after her 2024 performances and social media posts. Despite denials from Perry and sources, rumors persist into 2025.
The weight-loss drug Mounjaro's active ingredient, tirzepatide, is showing promise beyond metabolic health by slashing alcohol intake in animal models. A new study from the University of Gothenburg found it reduced voluntary consumption by over 50%, curbed binge drinking, and prevented relapse. This could signal a new avenue for treating alcohol use disorder through GLP-1/GIP receptor agonism.
A 33-year-old GP tried Mounjaro for obesity and was stunned by more than just weight loss—his 'food noise' vanished, alcohol interest dropped, and mood stabilized. After shedding almost two stone in three months, urges returned upon stopping, highlighting obesity's chronic nature. Now back on 5mg, he emphasizes long-term strategies beyond medication.
A woman known as @cartcrushuk on TikTok dropped 32% of her body weight using Mounjaro fat jabs and is now sharing the 'Mounjaro mistakes' she made along the way. From wasting time before starting to struggling with hydration and before photos, her honest advice focuses on protein, fiber, and basics for success. Her video has inspired thousands with nearly 15,000 views in four days.
For the first time, researchers have demonstrated that tirzepatide—the key ingredient in Mounjaro—slashes voluntary alcohol consumption by more than half in rodents while curbing relapse-like drinking. Published in eBioMedicine, this University of Gothenburg study highlights effects on the brain's reward system, including dopamine modulation in the lateral septum. These findings build on prior semaglutide research and suggest potential for alcohol use disorder therapies.
New research from Veterans' Affairs shows Ozempic and Wegovy users face double the risk of NAION—a serious vision loss condition—compared to SGLT2i drugs. Published in JAMA Ophthalmology, the study urges doctors to warn patients about potential permanent blindness from semaglutide-based GLP-1 medications. As lawsuits mount, understand the implications for diabetes and weight management.
Eli Lilly has overtaken Novo Nordisk in the GLP-1 gold rush, with Mounjaro and Zepbound now holding 60% of the U.S. market versus Ozempic and Wegovy's 39%. Backed by blockbuster revenue growth and superior weight loss results in head-to-head studies, Lilly's tirzepatide drugs are reshaping obesity and diabetes treatment. Investors and patients alike are taking notice of this shift.
